Dignitätsbeurteilung von Schilddrüsenknoten: Diagnostischer Zugewinn durch molekulare Feinnadelaspirationszytologie

Schlüsselwörter

Feinnadelaspirationszytologie - Schilddrüsenknoten - Molekulardiagnostik - papilläres Schilddrüsen- karzinom

Keywords

fine-needle aspiration biopsy - thyroid nodules - molecular diagnostics - papillary thyroid carcinoma

• Literatur

• 1 Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369
• 2 Chakravarty D, Santos E, Ryder M et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121: 4700-4711
• 3 Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-3949
• 4 Elisei R, Viola D, Torregrossa L et al. The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012; 97: 4390-4398
• 5 Eszlinger M, Krohn K, Hauptmann S et al. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 2008; 93: 3286-3294
• 6 Eszlinger M, Münz S, Ferraz C et al. Impact of molecular screening for mutations and rearrangements in 320 routine air dried fine needle aspiration (FNA) smears. Thyroid 2013; in press
• 7 Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab 2011; 96: 2016-2026
• 8 Ferraz C, Rehfeld C, Krogdahl A et al. Detection of PAX8/PPARG and RET/PTC Rearrangements is feasible in routine air-dried fine needle aspiration smears. Thyroid 2012; 22: 1025-1030
• 9 Franco AT, Malaguarnera R, Refetoff S et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A 2011; 108: 1615-1620
• 10 Fukahori M, Yoshida A, Hayashi H et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 2012; 22: 683-689
• 11 Gharib H, Papini E, Paschke R et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest 2010; 33: 1-50
• 12 Guerra A, Fugazzola L, Marotta V et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 2012; 97: 2333-2340
• 13 Kim CS, Zhu X. Lessons from mouse models of thyroid cancer. Thyroid 2009; 19: 1317-1331
• 14 Marotta V, Guerra A, Sapio MR et al. Are RET/PTC rearrangements in benign thyroid nodules of biological significance?. Thyroid 2010; 20: 1191-1192
• 15 Marotta V, Guerra A, Sapio MR et al. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 2011; 165: 499-507
• 16 Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-3397
• 17 Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098
• 18 Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of „follicular lesion of undetermined significance/atypia of undetermined significance“. Cancer Cytopathol 2010; 118: 17-23
• 19 Paschke R, Hegedus L, Alexander E et al. Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol 2011; 7: 354-361
• 20 Paschke R, Schmid KW, Gärtner R et al. Epidemiologie, Pathophysiologie, leitliniengerechte Diagnostik und Therapie von Schilddrüsenknoten. Med Klin 2010; 105: 80-87
• 21 Paschke R. Abklärung von Schilddrüsenknoten. Wann muss punktiert werden?. MMW Fortschr Med 2010; 152: 41-44
• 22 Piana S, Frasoldati A, Ferrari M et al. Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18 000 FNAs reported at the same institution during 1998-2007. Cytopathology 2010; 22: 164-173
• 23 Rossi M, Buratto M, Bruni S et al. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J Clin Endocrinol Metab 2012; 97: 2354-2361
• 24 Sapio MR, Guerra A, Marotta V et al. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 2011; 96: E916-E919
• 25 Xing M, Clark D, Guan H et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009; 27: 2977-2982
• 26 Yip L, Farris C, Kabaker AS et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 2012; 97: 1905-1912
• 27 Eszlinger M, Neustadt M, Ruschenburg I, Neumann A, Glaubitz R, Paschke R. Results of mutation and rearrangement detection setting of patients with nodular thyroid disease. . 56. Symposium der Deutschen Gesellschaft für Endokrinologie 2013